Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087113 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
A Phase 2 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00087113 is a Phase 2 study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 13 states.
The verdict
NCT00087113, a Phase 2 study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent cancer of the cervix.
Conditions Studied
Interventions
- DRUG pemetrexed disodium
Study Locations (20)
Ohio
- Case Comprehensive Cancer Center - Cleveland
- MetroHealth's Cancer Care Center at MetroHealth Medical Center - Cleveland
- Hillcrest Cancer Center at Hillcrest Hospital - Mayfield Heights
Missouri
- CCOP - Kansas City - Kansas City
- St. John's Regional Health Center - Springfield
New York
- SUNY Downstate Medical Center - Brooklyn
- SUNY Upstate Medical University Hospital - Syracuse
North Carolina
- Hope A Women's Cancer Center - Asheville
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill
Oklahoma
- Oklahoma University Medical Center - Oklahoma City
- Cancer Care Associates - Midtown Tulsa - Tulsa
Pennsylvania
- Rosenfeld Cancer Center at Abington Memorial Hospital - Abington
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest - Allentown
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
California
- Doctors Medical Center - Modesto
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087113
The ClinicalTrials.gov registry entry for NCT00087113 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which pemetrexed disodium is the first listed.
NCT00087113 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Ohio, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT00087113 about?
NCT00087113 is a clinical study titled "Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix". RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent cancer of the cervix.
What is the current status of trial NCT00087113?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-08.
What conditions does trial NCT00087113 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT00087113?
The interventions under investigation include: pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00087113?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087113 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.